The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma.
 
Brian Gastman
Stock and Other Ownership Interests - Castle Biosciences
Consulting or Advisory Role - Castle Biosciences; Quest Imaging
Speakers' Bureau - Castle Biosciences
Research Funding - Alkermes; Instil Bio; Merck; NeoImmuneTech; Quest Imaging
Travel, Accommodations, Expenses - Alkermes
 
Omid Hamid
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Aduro Biotech; Akeso Biopharma; Alkermes; Amgen; BeiGene; BioAtla; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Idera; Immunocore; Incyte; Iovance Biotherapeutics; Janssen; Merck; NextCure; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Philippa Gail Corrie
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Microbiotica; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Bartosz Chmielowski
Consulting or Advisory Role - Genentech; IDEAYA Biosciences; Iovance Biotherapeutics; Nektar; Novartis; OncoSec; Sanofi
Research Funding - Advenchen Laboratories (Inst); Array BioPharma (Inst); Ascentage Pharma (Inst); Atreca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Daiichi Sankyo (Inst); IDEAYA Biosciences (Inst); Idera (Inst); Immunocore (Inst); Infinity Pharmaceuticals (Inst); Instil Bio (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); Novartis (Inst); PACT Pharma (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Rgenix (Inst); Tolero Pharmaceuticals (Inst); Xencor (Inst)
 
Sajeve Samuel Thomas
Speakers' Bureau - Amgen; Bms; Genentech; ipsen; Merck; Novartis; Pfizer
 
Gregory A. Daniels
Honoraria - Bayer; Blueprint Medicines
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Nektar (Inst); Viralytics (Inst)
 
Evidio Domingo-Musibay
Honoraria - Regeneron
Consulting or Advisory Role - Castle Biosciences; Sanofi/Regeneron
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Clinigen Group (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst)
 
Donald P. Lawrence
No Relationships to Disclose
 
Eric D. Whitman
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Eisai; Merck Sharp & Dohme; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Castle Biosciences; Merck Sharp & Dohme; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Dynavax Technologies (Inst); Genentech/Roche (Inst); Iovance Biotherapeutics (Inst); Merck Sharp & Dohme (Inst); Oncolys BioPharma (Inst); OncoSec (Inst); Provectus (Inst); Toray Industries (Inst); Toray Industries (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Lighted Polyhedral surgical retractor; Nerve monitoring dissection device
 
Geoffrey Thomas Gibney
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exicure; Genentech; Merck; Novartis; Regeneron; Sapience Therapeutics
Research Funding - Exelixis (Inst); Lucerno Dynamics (Inst)
Other Relationship - Genentech
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Merck; Pfizer; Sanofi; Takeda
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Gan & Lee (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Immunocore (Inst); Intensity Therapeutics (Inst); Iovance Biotherapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Navire (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Seagen (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sumitomo Group (Inst); Takeda (Inst); Targovax (Inst)
(OPTIONAL) Uncompensated Relationships - Takeda
 
Yizhou Jiang
Employment - Instil Bio
Stock and Other Ownership Interests - Instil Bio
 
Audrey Kennedy
Employment - Instil Bio
Stock and Other Ownership Interests - Instil Bio
 
Jeff Aycock
Employment - Instil Bio
Leadership - Instil Bio
Stock and Other Ownership Interests - Instil Bio
 
Paul B. Robbins
Employment - Instil Bio
Stock and Other Ownership Interests - Instil Bio
Research Funding - Instil Bio
 
John Brian Le Gall
Employment - Instil Bio
Stock and Other Ownership Interests - Instil Bio
Patents, Royalties, Other Intellectual Property - Patent pending
 
Zachary Roberts
Employment - Instil Bio
Stock and Other Ownership Interests - Instil Bio
 
Robert E. Hawkins
Employment - Instil Bio
Stock and Other Ownership Interests - Bivictrix; Instil Bio
Consulting or Advisory Role - Anaveon; NovalGen
Other Relationship - BiVictriX
 
Amod Sarnaik
Honoraria - Medscape; MedStar Health; Physicans' Education Resource
Consulting or Advisory Role - B4CC; Defined Health; Gerson Lehrman Group; Guidepoint Global; Huron Consulting; Iovance Biotherapeutics; Istari; KeyQuest Health
Research Funding - Genentech (Inst); Iovance Biotherapeutics (Inst); Provectus (Inst)
Patents, Royalties, Other Intellectual Property - Compositions and methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy, filed March 20, 2014 U.S. Patent Application No. 61/955,970 and second Application No. 61/973,002 (Inst); Culture of Tumor-infiltrating lymphocytes from tumor digest, filed March 24, 2021 US Patent Application No. 17/279,327 (Inst); Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound, filed August 21, 2018 U.S. Patent Application No. 14/974,357; Rapid method for culture of tumor-infiltrating lymphocytes from core needle biopsies of solid tumors, filed January 2, 2018 U.S. Patent Application No. 62/612,915 (Inst); Tumor-infiltrating lymphocytes and stapled peptoid peptide hybrid peptidomimetics, filed October 11, 2018 U.S. Patent Application No. 16/157,174 (Inst)
Travel, Accommodations, Expenses - Iovance Biotherapeutics; Iovance Biotherapeutics